Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

January 20, 2023

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

October 12, 2021

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

News Conference News LINC 2020

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

January 31, 2020

EffPac: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

May 23, 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

March 06, 2019

PVI in Symptomatic Lower-Extremity PAD Offers Multiple Benefits, Even 2.5 Years Later

News Conference News ISET 2019

PVI in Symptomatic Lower-Extremity PAD Offers Multiple Benefits, Even 2.5 Years Later

February 07, 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

January 30, 2019

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

November 13, 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

September 24, 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

September 22, 2018

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

September 18, 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

September 13, 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

News Conference News ISET 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

February 17, 2017

Targeted Delivery of Dexamethasone Combats Restenosis in Femoropopliteal Lesions: DANCE Trial

News Conference News ISET 2017

Targeted Delivery of Dexamethasone Combats Restenosis in Femoropopliteal Lesions: DANCE Trial

February 15, 2017

News Conference News TCT 2016

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

November 07, 2016

News Conference News VIVA 2016

Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions

September 22, 2016

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

September 21, 2016

News Conference News ISET 2016

Drug-Coated Balloon Angioplasty Superior for In-Stent Restenosis of SFA, but Results Leave Much To Be Desired

Michael O'Riordan

February 10, 2016

News Conference News TCT 2015

IN.PACT SFA: Benefits of DCB Persist at 2 Years

October 14, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.